Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of first-in-class, synthetic small molecules that mimic natural peptides, today announced the appointment of Kate McKinley and Douglas S. Boothe to its Board of Directors. The appointments add experienced pharmaceutical industry CEOs with extensive commercialization, distribution and successful market access expertise to Maxwell’s board. 

Austin, TX – September 22, 2022 – Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic therapeutic compounds that mimic biomolecules, today announced that the Company will present new data on its CLAROMER™ platform’s ability to treat and prevent SARS-CoV-2 and other respiratory viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, United Kingdom from September 26-29, 2022.

Austin, TX – September 20, 2022 – Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell’s management team, bringing industry-leading leadership to support the company’s clinical R&D strategy and operations.

Austin, TX – April 22, 2022 – Maxwell Biosciences today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately. Dr. Rudnic brings more than 30 years of diverse experience in the biosciences industry.

Austin, TX – March 10, 2022 – Maxwell has developed a groundbreaking drug platform technology with the potential to profoundly impact global health. This funding will accelerate our efforts to develop a new class of drugs designed to fight viruses and other pathogens.